AR063057A1 - Metodo de inmunizacion contra los 4 serotipos de dengue - Google Patents

Metodo de inmunizacion contra los 4 serotipos de dengue

Info

Publication number
AR063057A1
AR063057A1 ARP070104316A ARP070104316A AR063057A1 AR 063057 A1 AR063057 A1 AR 063057A1 AR P070104316 A ARP070104316 A AR P070104316A AR P070104316 A ARP070104316 A AR P070104316A AR 063057 A1 AR063057 A1 AR 063057A1
Authority
AR
Argentina
Prior art keywords
dose
series
dengue virus
immunization method
dengue serotypes
Prior art date
Application number
ARP070104316A
Other languages
English (en)
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of AR063057A1 publication Critical patent/AR063057A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a un método para inducir proteccion contra los 4 serotipos de dengue en un paciente, que comprende: (a) una primera serie de administraciones (i) de una dosis de un virus de dengue para vacuna de un primer serotipo y de una dosis de un virus de dengue para vacuna de un segundo serotipo, y (ii) de una dosis de un virus de dengue para vacuna de un tercer serotipo y de una dosis de un virus de dengue para vacuna de un cuarto serotipo, y (b) una segunda serie de administraciones de dosis (i) y (ii), en donde las dosis (i) y (ii) se administran simultáneamente en distintos sitios anatomicos, y en donde la segunda serie se implementa al menos 30 días hasta como máximo 12 meses después de la primera serie.
ARP070104316A 2006-10-04 2007-09-28 Metodo de inmunizacion contra los 4 serotipos de dengue AR063057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.

Publications (1)

Publication Number Publication Date
AR063057A1 true AR063057A1 (es) 2008-12-23

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104316A AR063057A1 (es) 2006-10-04 2007-09-28 Metodo de inmunizacion contra los 4 serotipos de dengue

Country Status (15)

Country Link
US (2) US7718358B2 (es)
EP (3) EP2526965A1 (es)
JP (1) JP5269796B2 (es)
KR (1) KR20090064593A (es)
CN (2) CN101553251B (es)
AR (1) AR063057A1 (es)
AU (1) AU2007311792B2 (es)
BR (1) BRPI0719849A2 (es)
CA (1) CA2663885A1 (es)
FR (1) FR2906724B1 (es)
IL (2) IL197768A0 (es)
MX (1) MX2009003417A (es)
TW (2) TW201336508A (es)
WO (1) WO2008047023A2 (es)
ZA (1) ZA200901816B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2009109550A1 (en) 2008-03-05 2009-09-11 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CA2770888C (en) 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2011119628A2 (en) * 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
AU2012275319A1 (en) * 2011-06-29 2013-11-14 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of Dengue virus infection
EP2858668A1 (en) * 2012-06-10 2015-04-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
EP2877208B1 (en) * 2012-07-24 2021-05-12 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
JP2015524422A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
WO2014204892A1 (en) 2013-06-21 2014-12-24 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
CN106999568A (zh) 2014-12-22 2017-08-01 默沙东公司 登革病毒疫苗组合物及其使用方法
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
MX2018006500A (es) * 2015-11-27 2019-02-26 The Chemo Sero Therapeutic Res Institute Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antigenos.
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ATE297757T1 (de) 1997-02-28 2005-07-15 Acambis Inc Chimäre impfstoffe gegen flaviviren
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
JP2002540170A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱２型ウイルスワクチン
AU4040400A (en) * 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
AU4179200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
US6528065B1 (en) 1999-03-26 2003-03-04 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-3 virus vaccine
WO2000057907A2 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU3844101A (en) 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
ES2315221T3 (es) * 2000-05-30 2009-04-01 Mahidol University Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA3114957C (en) 2001-05-22 2022-02-08 Stephen S. Whitehead Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
EP1545572A4 (en) 2001-05-23 2006-04-12 Dendreon Corp CELL SURFACE PROTEINS ACTIVATED CONJUGATES AND THERAPEUTIC USES THEREOF
WO2002102828A2 (en) 2001-06-01 2002-12-27 Acambis, Inc. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
JP2005519639A (ja) * 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
BRPI0408774A (pt) 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
KR101536612B1 (ko) * 2005-06-17 2015-07-14 사노피 파스퇴르 약독화된 뎅기 혈청형 1 균주
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
KR20090064593A (ko) 2009-06-19
TW200826959A (en) 2008-07-01
TW201336508A (zh) 2013-09-16
FR2906724B1 (fr) 2009-03-20
IL197768A0 (en) 2011-08-01
FR2906724A1 (fr) 2008-04-11
EP2526965A1 (fr) 2012-11-28
EP2526964A1 (fr) 2012-11-28
ZA200901816B (en) 2010-06-30
US20100270202A1 (en) 2010-10-28
EP2077857A2 (fr) 2009-07-15
CN101553251B (zh) 2013-05-22
JP2010505801A (ja) 2010-02-25
CA2663885A1 (en) 2008-04-24
EP2077857B1 (fr) 2013-11-20
WO2008047023A2 (fr) 2008-04-24
CN103285386A (zh) 2013-09-11
TWI406673B (zh) 2013-09-01
CN101553251A (zh) 2009-10-07
BRPI0719849A2 (pt) 2014-04-29
US20080085288A1 (en) 2008-04-10
WO2008047023A3 (fr) 2008-10-23
AU2007311792A1 (en) 2008-04-24
US7718358B2 (en) 2010-05-18
AU2007311792B2 (en) 2013-05-02
MX2009003417A (es) 2009-04-09
JP5269796B2 (ja) 2013-08-21
IL224572A (en) 2014-06-30

Similar Documents

Publication Publication Date Title
AR063057A1 (es) Metodo de inmunizacion contra los 4 serotipos de dengue
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
AR061887A1 (es) Una composicion de vacuna contra el dengue
CY1123162T1 (el) Ελεγχομενης αποδεσμευσης φαρμακευτικα σκευασματα νιταζοξανιδης
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
PH12014501133A1 (en) Compositions and methods for treating hepatitis c virus
ECSP099780A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c
CU20100203A7 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de la hepatitis c
BR112012022676A2 (pt) composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit
BRPI0818183A2 (pt) reparo e regeneração do tecido renal usando células derivadas do tecido do cordão umbilical humano
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
BR112014001798A2 (pt) compostos de tetraciclina 9-aminometila substituídos
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
WO2013104995A3 (en) Compositions and methods for treating viral infections
CO6280408A2 (es) Vacuna de virus de la lengua azul y composiciones inmunogenicas procedimientos de uso y procedimeintos de la produccuion de la misma
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers
WO2013012835A3 (en) Sirna useful in the treatment of flavivirus infection
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
NO20090290L (no) Polyvalent vaksine mot salmonid alfavirusinfeksjoner
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)
MX2022001742A (es) Metodos para prevenir el dengue y la hepatitis a.

Legal Events

Date Code Title Description
FB Suspension of granting procedure